Xeris Biopharma Holdings, Inc.
XERS
$5.97
-$0.11-1.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 41.47% | 43.72% | 42.05% | 35.62% | 29.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.47% | 43.72% | 42.05% | 35.62% | 29.88% |
| Cost of Revenue | 12.19% | 15.58% | 17.68% | 47.96% | 35.13% |
| Gross Profit | 47.81% | 49.95% | 47.63% | 33.21% | 28.79% |
| SG&A Expenses | 13.23% | 11.56% | 8.76% | 13.24% | 12.10% |
| Depreciation & Amortization | 0.01% | 0.00% | 0.00% | 0.00% | -0.01% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.84% | 12.77% | 10.24% | 17.04% | 13.27% |
| Operating Income | 259.63% | 173.99% | 121.70% | 73.59% | 50.00% |
| Income Before Tax | 125.20% | 100.97% | 76.16% | 40.21% | 27.08% |
| Income Tax Expenses | -- | -- | 100.00% | -789.63% | -173.35% |
| Earnings from Continuing Operations | 126.64% | 101.01% | 75.22% | 46.28% | 30.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 126.64% | 101.01% | 75.22% | 46.28% | 30.01% |
| EBIT | 259.63% | 173.99% | 121.70% | 73.59% | 50.00% |
| EBITDA | 560.85% | 271.73% | 166.35% | 109.12% | 68.08% |
| EPS Basic | 123.75% | 99.47% | 76.50% | 49.57% | 35.13% |
| Normalized Basic EPS | 121.97% | 99.48% | 78.65% | 44.61% | 32.71% |
| EPS Diluted | 121.61% | 98.84% | 76.66% | 48.53% | 34.19% |
| Normalized Diluted EPS | 120.15% | 98.13% | 78.59% | 44.61% | 32.71% |
| Average Basic Shares Outstanding | 10.14% | 9.30% | 8.45% | 7.95% | 8.09% |
| Average Diluted Shares Outstanding | 16.01% | 14.08% | 10.87% | 7.95% | 8.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |